Bioregenx, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. reports the resignation of two directors, Gary Hennerberg and Gary Kiss, effective immediately.
OID
BRGX
Bioregenx, INCRobert Doran has resigned from his position as director of BioRegenx, Inc., effective January 31, 2025.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. has appointed Richard Janney to its board of directors and formed an audit committee, effective October 7, 2024.
OID
BRGX
Bioregenx, INCBioRegenx Inc. has completed a reverse merger with Findit, Inc., restated its financials for 2022 and 2023, and provided unaudited pro forma combined financial information for the year ended December 31, 2023.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. announces the resignation of Sherri Adams as an officer and director, effective July 17, 2024, to pursue other business interests.
OID
BRGX
Bioregenx, INCJody M. Walker has resigned from the BioRegenx Board of Directors effective July 13, 2024, due to her retirement.
OID
BRGX
Bioregenx, INCBioRegenx has engaged a new independent auditor, Weinberg & Company, and declared that its previously issued financial statements for the quarter ended March 31, 2024, should no longer be relied upon.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. has dismissed BF Borgers CPA PC as its independent registered public accounting firm, effective May 15, 2024, due to the firm's inability to practice before the SEC.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. has successfully completed its merger with Findit, Inc., and is now focused on expanding its product offerings and market presence.